Abstract | OBJECTIVE: METHODS AND RESULTS: A randomized, 8-week, cross-over, placebo-controlled, double-blind clinical trial was performed in 19 patients with type 2 diabetes. Standardized 6-h oral fat-loading tests were performed after each treatment period. During placebo treatment, blood leukocytes increased to a maximum 6-h postprandially, due to significant increases in neutrophils and lymphocytes. Concomitant postprandial increases were observed for IL-6 and IL-8, the major chemokines responsible for leukocyte recruitment. Rosiglitazone reduced the incremental area under the curves (dAUCs) for IL-6 (-63%, p<0.01) and IL-8 (-16%, p<0.05). The dAUC for leukocytes decreased with 37% (p<0.05), due to a specific reduction of neutrophils (-39%, p<0.05). CONCLUSIONS: CONDENSED ABSTRACT:
|
Authors | J P H van Wijk, M Castro Cabezas, B Coll, J Joven, T J Rabelink, E J P de Koning |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 186
Issue 1
Pg. 152-9
(May 2006)
ISSN: 0021-9150 [Print] Ireland |
PMID | 16137694
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Cytokines
- Hypoglycemic Agents
- Thiazolidinediones
- Rosiglitazone
|
Topics |
- Adult
- Aged
- Biomarkers
(blood)
- Cross-Over Studies
- Cytokines
(blood, drug effects)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Leukocyte Count
- Leukocytes
(drug effects)
- Male
- Middle Aged
- Postprandial Period
(drug effects)
- Prospective Studies
- Rosiglitazone
- Thiazolidinediones
(therapeutic use)
- Treatment Outcome
|